AMTIライブシグナル | Getagraph.comで利益を最大化

Live Chart Being Loaded With Signals

Commentary (27 12月 2023 @ 05:59):

Stats
本日の出来高	235 210
平均出来高	320 195
時価総額	11.01M
EPS	$0 ( 2024-03-14 )
次の収益日	( $0 ) 2024-05-09
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	-0.139
ATR14	$0.0200 (7.60%)

Insider Trading

Date	Person	Action	Amount	type
2023-12-27	Epiq Capital Group, Llc	Sell	2 149 292	Common Stock
2023-12-27	Epiq Capital Group, Llc	Sell	3 394 948	Common Stock
2023-12-27	Epiq Capital Group, Llc	Sell	2 500 000	Common Stock
2023-12-27	Epiq Capital Group, Llc	Sell	293 278	Common Stock
2023-12-27	Vandevender Aaron	Sell	212 659	Common Stock

INSIDER POWER
-68.14
Last 100 transactions
Buy: 3 477 833 \| Sell: 13 394 035

ボリューム相関

長: 0.02 (neutral)

短: 0.79 (moderate)

Signal:(62.898) Neutral

Applied Molecular 相関

10 最も正の相関
WOOF	0.969
WKEY	0.967
JAN	0.961
NMRD	0.96
MTLS	0.958
PODD	0.957
QRTEA	0.956
STIM	0.956
GERN	0.955
ENNV	0.955

10 最も負の相関
IGTA	-0.965
NVCN	-0.953
OHAA	-0.952
LCA	-0.951
TIOA	-0.949
BRIVU	-0.949
FTII	-0.949
HDSN	-0.948
MSDA	-0.946
CBRG	-0.941

知っていましたか？

相関は、2つの変数間の関係を説明する統計的指標です。相関係数は-1から1までの値を取り、-1は完全な負の相関（1つの変数が増加すると、もう一方は減少する）、1は完全な正の相関（1つの変数が増加すると、もう一方も増加する）、0は相関がないことを示します（変数間に関係がない）。

相関は、株式だけでなく、どの2つの変数間の関係にも適用できます。これは、金融、経済学、心理学などの分野で一般的に使用されています。

Applied Molecular 相関 - 通貨/商品

0.84
( strong )

0.32
( neutral )

0.00
( neutral )

0.67
( moderate )

-0.19
( neutral )

-0.86
( strong negative )

Applied Molecular 財務諸表

Annual	2022
収益:	$0
総利益:	$0 (0.00 %)
EPS:	$-3.23

FY	2022
収益:	$0
総利益:	$0 (0.00 %)
EPS:	$-3.23

FY	2021
収益:	$0.00
総利益:	$0.00 (0.00 %)
EPS:	$-4.38

FY	2020
収益:	$0.00
総利益:	$0.00 (0.00 %)
EPS:	$-2.91

Financial Reports:

No articles found.

Applied Molecular

Applied Molecular Transport Inc., a clinical-stage biopharmaceutical company, engages in the design and development of a pipeline of oral and respiratory biologic product candidates to treat autoimmune, inflammatory, metabolic, and other diseases. The company's lead product candidate is AMT-101, a gastrointestinal (GI) selective oral fusion of rhIL-10 that is in Phase II clinical trial for the treatment of ulcerative colitis and related inflammatory indications. It develops AMT-126, a GI-selective oral fusion of interleukin 22, which is in a Phase I clinical trial for diseases related to intestinal epithelium barrier function defects. The company, through its technology platform, designs and develops various oral biologic therapeutic modalities, such as peptides, proteins, antibodies, antibody fragments, and ribonucleic acid therapeutics. Applied Molecular Transport Inc. was founded in 2010 and is headquartered in South San Francisco, California.